RxDoctor Payments Data

Pearl Kwong, MD

Pediatric Dermatology · Jacksonville, FLNPI 1043309909

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,370,698 of the $3,187,351 with a category attached, or 74.4%. It is spread thinly across 45 manufacturers, the largest accounting for just 18.1%. 2025 is the largest year on record at $748,093, 2.5 times the $304,636 reported in 2019.

$3,187,351in general payments, 2019–2025

Across 3,645 payments — averaging $874.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$578K
  • Sanofi$493K
  • Pfizer$337K
  • Incyte Corporation$288K
  • Lilly USA, LLC$265K
  • AbbVie$261K
  • plus $964K from 39 others
$4,839,013in research payments, 2019–2025

Across 796 payments — averaging $6079.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1.5M
  • Eli Lilly$1.4M
  • Amgen$752K
  • AbbVie$258K
  • Pfizer$191K
  • Aclaris Therapeutics, Inc.$169K
  • plus $588K from 12 others

What the payments were for

  • Consulting fees$351,59611%
  • Speaking & faculty fees$2,370,69874%
  • Travel & lodging$363,63211%
  • Food & beverage$100,9613%
  • Education$3470%
  • Gifts$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric dermatology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,033
Medicare patients
13
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatric dermatology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →